Tff Pharmaceuticals Inc (TFFP) concluded trading on Thursday at a closing price of $0.31, with 6.55 million shares of worth about $2.03 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.53% during that period and on December 05, 2024 the price saw a loss of about -1.82%. Currently the company’s common shares owned by public are about 4.44M shares, out of which, 3.98M shares are available for trading.
Stock saw a price change of 0.98% in past 5 days and over the past one month there was a price change of -83.26%. Year-to-date (YTD), TFFP shares are showing a performance of -95.61% which decreased to -96.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.27 but also hit the highest price of $11.00 during that period. The average intraday trading volume for Tff Pharmaceuticals Inc shares is 1.22 million. The stock is currently trading -58.87% below its 20-day simple moving average (SMA20), while that difference is down -80.12% for SMA50 and it goes to -88.84% lower than SMA200.
Tff Pharmaceuticals Inc (NASDAQ: TFFP) currently have 4.44M outstanding shares and institutions hold larger chunk of about 12.80% of that.
The stock has a current market capitalization of $1.36M and its 3Y-monthly beta is at 1.06. It has posted earnings per share of -$6.45 in the same period. It has Quick Ratio of 0.89 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TFFP, volatility over the week remained 19.69% while standing at 22.09% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on May 19, 2022 offering a Buy rating for the stock and assigned a target price of $22 to it. Coverage by H.C. Wainwright stated Tff Pharmaceuticals Inc (TFFP) stock as a Buy in their note to investors on February 08, 2021, suggesting a price target of $31 for the stock. On December 07, 2020, B. Riley Securities Initiated their recommendations, while on August 17, 2020, Maxim Group Reiterated their ratings for the stock with a price target of $18. Stock get a Buy rating from Maxim Group on July 08, 2020.
